QUINCE THERAPEUTICS INC (QNCX)

Weekly Summary (2025-05-12)

Highlights

Potential early conclusion of enrollment for Phase 3 NEAT clinical trial by end of June 2025 to align with cash runway
All 19 study sites activated, including new sites in the U.K. and Europe
Low screen failure rate of 10% in NEAT trial
Positive cash balance expected to maintain through topline results reporting

Challenges

Slower than anticipated enrollment due to challenging academic site environment
Uncertain macroeconomic environment
Need for additional funding to extend cash runway beyond Q1 2026

Catalysts

Topline results from NEAT trial expected by early 2026
NDA and MAA submissions planned in second half of 2026, assuming positive results

Outlook

Quince Therapeutics is strategically positioning itself to maximize its cash runway while aiming for significant trial results in early 2026.

Upcoming Events

Jun 30, 2025, 7:00:00 AM UTC

Phase 3 NEAT Clinical Trial Enrollment Completion

Quince Therapeutics expects to complete enrollment for its Phase 3 NEAT clinical trial by the end of Q2 2025, with new site activations accelerating the process.

trial completion

Oct 1, 2025, 7:00:00 AM UTC

Phase 3 NEAT Clinical Trial Topline Results

Quince Therapeutics anticipates topline results from its Phase 3 NEAT clinical trial in Q4 2025, following expected completion of enrollment in Q2 2025.

clinical readout